



IMMUNOPRECISE ANTIBODIES ATTENDING J.P. MORGAN HEALTHCARE CONFERENCE WEEK JANUARY 8-11, 2018

ImmunoPrecise Antibodies Ltd. and U-Protein Express BV announce that ImmunoPrecise will be attending the J.P. Morgan 36th Annual Healthcare Conference running from January 8-11, 2018 in San Francisco, California.

Thirty-five years ago, J.P. Morgan launched Wall Street's premier investor conference focused exclusively on companies defining the healthcare industry. The J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry. In 2018, J.P. Morgan expects more than 400 companies, both public and private, to deliver presentations to more than 8,000 attendees. The conference provides a unique opportunity for investors to visit with so many inter-related industry leaders in one setting.

For further information please contact:

ImmunoPrecise Antibodies Ltd.
Phone: 1-250-483-0803
3204-4464 Markham Street.
Victoria, BC V8Z 7X8
www.immunoprecise.com

For investor relations please contact:

Rob Gamley
Phone: 1-604-689-7422
Email: rob@contactfinancial.com
Contact Financial Corp.
1450 – 701 West Georgia St.
Vancouver, BC V7Y 1G5

Forward Looking Information

This news release contains statements that, to the extent they are not recitations of historical fact, may constitute "forward-looking statements" within the meaning of applicable Canadian securities laws. The Company uses words such as "may", "would", "could", "will", "likely", "expect", "believe", "intend" and similar expressions to identify forward-looking statements. Any such forward-looking statements are based on assumptions and analyses made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments. However, whether actual results and developments will conform to the Company's expectations and predictions is subject to any number of risks, assumptions and uncertainties. Many factors could cause the Company's actual results to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors include, among other things, the Company closing its acquisition of Preclinics, and such risks and uncertainties described in the Company's Filing Statement dated December 13, 2016 which can be accessed at www.sedar.com. The "forward-looking statements" contained herein speak only as of the date of this press release and, unless required by applicable law, the Company undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.